Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

P53 Protein Expression Correlates with Adverse Outcome in Low-Risk Myelodysplastic Syndromes

Francesca Donatelli, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Alexander e Smith, PhD, Jon Salisbury, Syed A Mian, BSc, M.Phil, Robin M. Ireland, FRCP, FRCPath, Abu Arqoub Hadil, Victoria T Potter, Ghulam J. Mufti, MD PhD

Blood (2016) 128 (22): 5505.

https://doi.org/10.1182/blood.V128.22.5505.5505

Published: 2016

Journal Articles

Autologous Ex-Vivo Regulatory T Cells(Tregs) Expansion in Aplastic Anemia for Potential Clinical Use

Benedetta Costantini, MD, Shahram Kordasti, MD PhD, Seidl Thomas, Smith Alexander, PhD, Mian Syed, PhD, Aytug Kizilors, PhD, Martinez-Llordella Marc, PhD, Judith C Marsh, MD, Ghulam J. Mufti, MD PhD

Blood (2015) 126 (23): 3617.

https://doi.org/10.1182/blood.V126.23.3617.3617

Published: 2015

Journal Articles

The Safety and Tolerability of Azacitidine (AZA) Are Comparable in Patients with Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndromes (MDS)

John F. Seymour, MBBS, PhD, Lewis R. Silverman, MD, Hartmut Döhner, Prof. MD, Pierre Fenaux, MD PhD, Ghulam J. Mufti, MD PhD, Valeria Santini, MD, Mark D. Minden, MD PhD, Richard M. Stone, MD, Lela M. Lucy, PhD, Stephen Songer, PharmD, Donna Dougherty, BSN, Randy Hinkle, RPh, MBA, Dominique Gambini, MD, C.L. Beach, PharmD, Hervé Dombret

Blood (2015) 126 (23): 3754.

https://doi.org/10.1182/blood.V126.23.3754.3754

Published: 2015

Journal Articles

Impact of Finding of Low Level Kinase Domain Mutations Using Ultra Deep Next Generation Sequencing in Patients with Chronic Phase CML

Aytug Kizilors, PhD, Elena Crisa, MD, Nicholas Lea, PhD, Steven Best, PhD, Mian Syed, PhD, Robin M. Ireland, FRCP, FRCPath, Maadh Aldouri, FRCPath, Christopher Pocock, Timothy Corbett, FRCP, FRCPath, Emily Elizabeth Bart-Smith, MRCP,BSc, Richard Gale, FRCPath, FRCP, Clare Wykes, FRCPath, FRCP, Simon Weston-Smith, FRCP, FRCPath, Donal McLornan, MDPhD, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Ghulam J. Mufti, MD PhD, Hugues de Lavallade, MD PhD

Blood (2015) 126 (23): 347.

https://doi.org/10.1182/blood.V126.23.347.347

Published: 2015

Journal Articles

Safety of Lenalidomide (LEN) 10mg in Non-Del(5q) Versus Del(5q) in the Treatment of Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (MDS): Pooled Analysis of Treatment-Emergent Adverse Events (TEAEs)

Antonio Almeida, MD PhD, Valeria Santini, MD, Stefanie Gröpper, MD, Anna Jonasova, MD, Norbert Vey, Aristoteles Giagounidis, MD PhD, Eva Hellström-Lindberg, MD PhD, Ghulam J. Mufti, MD PhD, Guillermo Sanz, MD PhD, Barry Skikne, MD, Albert Hoenekopp, MD, Francis Séguy, Jianhua Zhong, PhD, Pierre Fenaux, MD PhD

Blood (2015) 126 (23): 2880.

https://doi.org/10.1182/blood.V126.23.2880.2880

Published: 2015

Journal Articles

Dendritic Cell Subsets in Bone Marrow and Peripheral Blood of Patients with Myelodysplastic Syndromes Display Numeric and Functional Defects

Nathalie van Leeuwen-Kerkhoff, MD, Theresia M. Westers, PhD, Hetty J Bontkes, PhD, Shahram Kordasti, MD PhD, Ghulam J. Mufti, MD PhD, Tanja D de Gruijl, PhD, Arjan A van de Loosdrecht, MD PhD

Blood (2015) 126 (23): 4109.

https://doi.org/10.1182/blood.V126.23.4109.4109

Published: 2015

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (HCT) for Advanced Mycosis Fungoides and Sezary Syndrome (MF/SS): Impact of Increasing the Use of Unrelated Donors (UD) - the EBMT Lymphoma Working Party Experience

Blood (2015) 126 (23): 4403.

https://doi.org/10.1182/blood.V126.23.4403.4403

Published: 2015

Journal Articles

Prevalence and Impact on Outcomes of Additional Karyotypic Abnormalities in Patients (Pts) with Myelodysplastic Syndromes (MDS) and Del(5q) from the MDS-003 and MDS-004 Studies

Aristoteles Giagounidis, MD PhD, Alan F. List, MD, Eva Hellström-Lindberg, MD PhD, Ghulam J. Mufti, MD PhD, Brigitte Schlegelberger, MD PhD, John Morrill, Chengqing Wu, PhD, Barry S. Skikne, MD, Pierre Fenaux, MD PhD, Gudrun Göhring, MD

Blood (2015) 126 (23): 1680.

https://doi.org/10.1182/blood.V126.23.1680.1680

Published: 2015

Journal Articles

Romiplostim in Thrombocytopenic Patients (Pts) with Low-Risk or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) Results in Reduced Bleeding without Impacting Leukemic Progression: Updated Follow-up Results from a Randomized, Double-Blind, Placebo (PBO)-Controlled Study

Hagop Kantarjian, MD, Ghulam J. Mufti, MD PhD, Pierre Fenaux, MD PhD, Mikkael A. Sekeres, MD MS, Jeffrey Szer, MB BS FRACP, Uwe Platzbecker, MD, Andrea Kuendgen, MD, Gianluca Gaidano, Wieslaw Wiktor-Jedrzejczak, MD PhD, Janet Franklin, MD MPH, Aristoteles Giagounidis, MD

Blood (2015) 126 (23): 2863.

https://doi.org/10.1182/blood.V126.23.2863.2863

Published: 2015

Journal Articles

Efficacy and Safety of Lenalidomide (LEN) Versus Placebo (PBO) in RBC-Transfusion Dependent (TD) Patients (Pts) with IPSS Low/Intermediate (Int-1)-Risk Myelodysplastic Syndromes (MDS) without Del(5q) and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents (ESAs): Results from a Randomized Phase 3 Study (CC-5013-MDS-005)

Blood (2014) 124 (21): 409.

https://doi.org/10.1182/blood.V124.21.409.409

Published: 2014

Journal Articles

Clinical Characteristics and Treatment Allocations in Patients with Myelodysplastic Syndromes and Monosomy 7: Results from an International Multicenter Study Suggest That Hypomethylating Agents Significantly Improve Overall- and AML-Free Survival in Patients Classified As Very High Risk By IPSS-R

Julie Schanz, MD PhD, Friederike Braulke, MD, Ghulam J. Mufti, MD PhD, Elena Crisà, Austin Kulasekararaj, Kathrin Nachtkamp, MD, Ulrich Germing, Stefan Schmitz, MD PhD, Peter Haas, MD, Michael Lübbert, Catharina Müller-Thomas, MD, Katharina Götze, Uwe Platzbecker, MD, Florian Nolte, Wolf-Karsten Hofmann, MD PhD, Detlef Haase

Blood (2014) 124 (21): 4656.

https://doi.org/10.1182/blood.V124.21.4656.4656

Published: 2014

Journal Articles

Multi-Center Study on Myelodysplastic Syndromes with Isolated Partial or Total Loss of Chromosome 7

Elena Crisà, MD, Esperanza Such, PhD, Steven Best, PhD, Austin Kulasekararaj, José Cervera, Vera Adema, PhDstudent, Nicholas Lea, PhD, Dario Ferrero, MD PhD, Bernardino Allione, Julie Schanz, MD PhD, Detlef Haase, MD, Guillermo F. Sanz, MD PhD, Francesco Sole, PhD, Ghulam J. Mufti, MD PhD

Blood (2014) 124 (21): 4662.

https://doi.org/10.1182/blood.V124.21.4662.4662

Published: 2014

Journal Articles

King’s College Hospital FCC Conditioning for Severe Aplastic Anemia Induces Tolerance with Mixed T-Cell Chimerism and Extremely Low Incidence of Gvhd

Francesco Grimaldi, MD, Linda D Barber, PhD, Pilar Perez-Abellan, MSc, Rosemary Grain, Victoria T Potter, MD FRCPA, FRACP, Austin Kulasekararaj, Donal McLornan, MD PhD FRCPath, Kavita Raj, MD PhD FRCPath, Hugues de Lavallade, MD PhD, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Ghulam J. Mufti, MD PhD, Judith C Marsh, MD

Blood (2014) 124 (21): 1594.

https://doi.org/10.1182/blood.V124.21.1594.1594

Published: 2014

Journal Articles

Prevalence and Clinical Impact of Additional Cytogenetic Abnormalities in Patients (Pts) with Myelodysplastic Syndromes (MDS) and Deletion 5q from the MDS-003 and MDS-004 Studies

Aristoteles Giagounidis, MD PhD, Alan F. List, MD, Eva Hellstrom-Lindberg, MD PhD, Ghulam J. Mufti, MD PhD, Brigitte Schlegelberger, MD PhD, John Morrill, Chengqing Wu, PhD, Barry Skikne, MD, Pierre Fenaux, MD PhD, Gudrun Göhring, MD

Blood (2014) 124 (21): 3270.

https://doi.org/10.1182/blood.V124.21.3270.3270

Published: 2014

Journal Articles

Characteristics and Outcome Of Acute Myeloid Leukemia Following Breast Cancer: Analysis Of 408 Cases and Controls

Marine Gilabert, MD, Jean-Baptiste Micol, Austin G Kulasekararaj, MD, PhD, Stephane de Botton, Claude Chahine, Benjamin Esterni, Ph.D., Ghulam J. Mufti, MD, PhD, Norbert Vey, MD PhD, Thomas Prebet, MD PhD

Blood (2013) 122 (21): 1408.

https://doi.org/10.1182/blood.V122.21.1408.1408

Published: 2013

Journal Articles

Chronic Relapsing Remitting Sweet’s Syndrome- a Harbinger Of Myelodysplastic Syndrome (MDS), Single Centre Analysis Of 31 Patients

Austin G Kulasekararaj, Shahram Y Kordasti, Tanya Basu, Jon Salisbury, Anthony du Vivier, Ghulam J. Mufti, MD, PhD

Blood (2013) 122 (21): 2793.

https://doi.org/10.1182/blood.V122.21.2793.2793

Published: 2013

Journal Articles

Outcomes In RBC Transfusion-Dependent Patients (Pts) With Low-/Intermediate (Int)-1-Risk Myelodysplastic Syndromes (MDS) With Isolated Deletion 5q Treated With Lenalidomide (LEN): A Subset Analysis From The MDS-004 Study

Blood (2013) 122 (21): 2753.

https://doi.org/10.1182/blood.V122.21.2753.2753

Published: 2013

Journal Articles

Myeloid Derived Suppressor Cell Expansion Correlates With Increased regulatory T Cells In Myelodysplastic Syndrome

Astrid Olsnes Kittang, MD, PhD, Shahram Kordasti, MD, PhD, Kristoffer Evebø Sand, MD, Pilar Perezabellan, Thomas Seidl, Kristin Paulsen Rye, Karen Marie Hagen, Geir Hallan, MD, PhD, Austin G Kulasekararaj, MD, PhD, Øystein Bruserud, MD, PhD, Ghulam J. Mufti, MD, PhD

Blood (2013) 122 (21): 2766.

https://doi.org/10.1182/blood.V122.21.2766.2766

Published: 2013

Journal Articles

Internal Tandem Duplication Mutation Of FLT3 (FLT3/ITD) Induces Increased Homologous Recombination DNA Repair Activity, Drug Resistance and Sister Chromatid Exchanges In Acute Myeloid Leukaemia (AML)

Terry J Gaymes, DPhil, David C Darling, PhD, Ghulam J. Mufti, MD, PhD

Blood (2013) 122 (21): 1244.

https://doi.org/10.1182/blood.V122.21.1244.1244

Published: 2013

Journal Articles

Azacitidine Treatment For Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia Harboring Chromosome 3q Abnormalities

Anne Wanquet, Celine Berthon, Marie Sebert, Clémence Roux, Austin Kulasekararaj, MD PHD, Jean-Baptiste Micol, Raphael Itzykson, Sylvain Thepot, Christian Recher, MD PhD, Jacques Delaunay, MD, Francois Dreyfus, MD, Ghulam J. Mufti, MD, PhD, Pierre Fenaux, MD, PhD, Norbert Vey, MD, Thomas Prebet, MD, PhD

Blood (2013) 122 (21): 1512.

https://doi.org/10.1182/blood.V122.21.1512.1512

Published: 2013

NARROW

P53 Protein Expression Correlates with Adverse Outcome in Low-Risk Myelodysplastic Syndromes

Autologous Ex-Vivo Regulatory T Cells(Tregs) Expansion in Aplastic Anemia for Potential Clinical Use

The Safety and Tolerability of Azacitidine (AZA) Are Comparable in Patients with Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndromes (MDS)

Impact of Finding of Low Level Kinase Domain Mutations Using Ultra Deep Next Generation Sequencing in Patients with Chronic Phase CML

Safety of Lenalidomide (LEN) 10mg in Non-Del(5q) Versus Del(5q) in the Treatment of Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (MDS): Pooled Analysis of Treatment-Emergent Adverse Events (TEAEs)

Dendritic Cell Subsets in Bone Marrow and Peripheral Blood of Patients with Myelodysplastic Syndromes Display Numeric and Functional Defects

Allogeneic Hematopoietic Cell Transplantation (HCT) for Advanced Mycosis Fungoides and Sezary Syndrome (MF/SS): Impact of Increasing the Use of Unrelated Donors (UD) - the EBMT Lymphoma Working Party Experience

Prevalence and Impact on Outcomes of Additional Karyotypic Abnormalities in Patients (Pts) with Myelodysplastic Syndromes (MDS) and Del(5q) from the MDS-003 and MDS-004 Studies

Romiplostim in Thrombocytopenic Patients (Pts) with Low-Risk or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) Results in Reduced Bleeding without Impacting Leukemic Progression: Updated Follow-up Results from a Randomized, Double-Blind, Placebo (PBO)-Controlled Study

Clinical Characteristics and Treatment Allocations in Patients with Myelodysplastic Syndromes and Monosomy 7: Results from an International Multicenter Study Suggest That Hypomethylating Agents Significantly Improve Overall- and AML-Free Survival in Patients Classified As Very High Risk By IPSS-R

Multi-Center Study on Myelodysplastic Syndromes with Isolated Partial or Total Loss of Chromosome 7

King’s College Hospital FCC Conditioning for Severe Aplastic Anemia Induces Tolerance with Mixed T-Cell Chimerism and Extremely Low Incidence of Gvhd

Prevalence and Clinical Impact of Additional Cytogenetic Abnormalities in Patients (Pts) with Myelodysplastic Syndromes (MDS) and Deletion 5q from the MDS-003 and MDS-004 Studies

Characteristics and Outcome Of Acute Myeloid Leukemia Following Breast Cancer: Analysis Of 408 Cases and Controls

Chronic Relapsing Remitting Sweet’s Syndrome- a Harbinger Of Myelodysplastic Syndrome (MDS), Single Centre Analysis Of 31 Patients

Outcomes In RBC Transfusion-Dependent Patients (Pts) With Low-/Intermediate (Int)-1-Risk Myelodysplastic Syndromes (MDS) With Isolated Deletion 5q Treated With Lenalidomide (LEN): A Subset Analysis From The MDS-004 Study

Myeloid Derived Suppressor Cell Expansion Correlates With Increased regulatory T Cells In Myelodysplastic Syndrome

Internal Tandem Duplication Mutation Of FLT3 (FLT3/ITD) Induces Increased Homologous Recombination DNA Repair Activity, Drug Resistance and Sister Chromatid Exchanges In Acute Myeloid Leukaemia (AML)

Azacitidine Treatment For Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia Harboring Chromosome 3q Abnormalities

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only